We show that reducing SMPD1 activity, either by partial genetic deficiency or mostly important by preventative or therapeutic pharmacological inhibition, is beneficial for liver function in the acute phase of sepsis and for preventing inflammation, HSC activation and hepatic fibrogenesis as a prolonged consequence of sepsis. This evidence concerns the gene SMPD1 and Sepsis.